The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)

Inclusion Criteria: * Patient with primary liver transplantation recipients * Male and Female aged ≥19 and ≤65 * Patient with ABO blood type correspond with Donor's blood type * Patient who agreement with written informed consent * Patient who Women if had childbearing potential must have a negative serum or urine pregnancy test at the screening visit and agreement with contraception Exclusion Criteria: * Patient with secondary liver transplantation(LT) recipient or other organ transplantation recipient in past or current * Patient with multi-organ transplantation recipient * Patient with dual-graft transplantation recipient * Patient who used body artificial liver before LT * Cr level \>2.0mg/dL in screening * WBC \<2,000/mm3 or ANC \<900/mm3 or PLT \<30,000/mm3 in screening * Patient who experienced severe gastrointestinal disorder so investigator judge the man's participation impossible * Patient who experienced severe infection (need to treatment) * Patient or Donor with HIV positive * Patient who need to treat with immunosuppressant or chemistry therapy * Patient who had taken immunosuppressant within 30days before LT (except to take Corticosteroids and Tacrolimus due to protocol)